The US Food and Drug Administration has noted a higher - than - expected rate of suicide attempts in open - label extensions of controlled trials
of duloxetine for stress urinary incontinence.
A new study indicates that the benefits
of duloxetine, a drug used in Europe to treat stress incontinence in women, do not outweigh the harms.
Eli Lilly makes its first attempt at FDA approval
of duloxetine.
Not exact matches
Those taking
duloxetine had fewer symptoms
of depression and less physical pain.
The FDA reviews more liver health data and approves
duloxetine for depression and diabetic neuropathy (pain), based on another set
of clinical trials.
One
of their molecules becomes known as
duloxetine, later branded Cymbalta.
Duloxetine, a drug approved in Canada, the US and Europe to treat major depression, is approved in Europe to treat stress urinary incontinence — involuntary leakage
of urine during exertion, sneezing or coughing — that affects an estimated 1 in 10 women.
Next Page: Cymbalta [pagebreak] Cymbalta How it works: Approved in 2008 for use in fibromyalgia (and previously approved for diabetic retinopathy and depression), Cymbalta (
duloxetine) is a serotonin and norepinephrine reuptake inhibitor (SNRI)-- a type
of antidepressant that raises the levels
of the neurotransmitters serotonin and norepinephrine in the brain and body.